Evidence map›Paper›PMID 37953220›Full record

ReviewAnnals of palliative medicine2023

Pivoting to telemedicine in a single-day multidisciplinary liver tumor clinic during COVID-19: the Texas Liver Tumor Center experience.

Katherine S Crow, Fred F Poordad, Glenn A Halff, Francisco G Cigarroa, Eugenia Tsai, Irma V Infante, Sukeshi Patel Arora

Open access · diamondAbstract readReview
In one paragraph

Review in Annals of palliative medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Katherine S CrowTexas Liver Tumor Center, University Health Transplant Institute, University Health San Antonio, San Antonio, TX, USA.
Fred F PoordadTexas Liver Tumor Center, University Health Transplant Institute, University Health San Antonio, San Antonio, TX, USA; Texas Liver Institute/UT Health San Antonio, San Antonio, TX, USA.
Glenn A HalffTexas Liver Tumor Center, University Health Transplant Institute, University Health San Antonio, San Antonio, TX, USA.
Francisco G CigarroaTexas Liver Tumor Center, University Health Transplant Institute, University Health San Antonio, San Antonio, TX, USA.
Eugenia TsaiTexas Liver Tumor Center, University Health Transplant Institute, University Health San Antonio, San Antonio, TX, USA; Texas Liver Institute/UT Health San Antonio, San Antonio, TX, USA.
Irma V InfanteTexas Liver Tumor Center, University Health Transplant Institute, University Health San Antonio, San Antonio, TX, USA.
Sukeshi Patel AroraTexas Liver Tumor Center, University Health Transplant Institute, University Health San Antonio, San Antonio, TX, USA; Division of Hematology/Oncology, Department of Medicine, Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX, USA.
Texas Liver Institute · USThe University of Texas Health Science Center at Houston · USThe University of Texas Health Science Center at San Antonio · US

Funding

TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Lei Zheng · 1991 to 2026
$59.1M
NCI NIH HHS P30 CA054174
6 · The paper itself

Abstract

Cancer guidelines recommend that all patients with hepatocellular carcinoma (HCC) have an evaluation by a multidisciplinary team to assess liver health, stage the cancer, and discuss treatment and palliative care options. Coronavirus disease 2019 (COVID-19) had a catastrophic impact on patients with cancer resulting in increased disease burden due to late diagnosis and treatment delays. Late diagnosis has highlighted the need for the early intervention of palliative care for patients with HCC. Conversion to telemedicine has been essential to caring for patients with all stages of cancer without added delays. Texas Liver Tumor Center (TLTC) offers patients with liver cancer at any stage a single-day multidisciplinary evaluation with tumor board review facilitating the early integration of treatment and palliative care services. National Comprehensive Cancer Network (NCCN) guidelines support increasing and improving access to palliative care. TLTC allows for the early integration of palliative care within a 1-day clinic model with an incorporated tumor board. This unique model of patient care decreases the burden of separate patient visits, may expedite the time from diagnosis to first treatment, facilitates the early intervention of palliative care specialists, and allows for optimal screening for clinical trials. In this review, we will provide an overview of the current multidisciplinary models of care for HCC and describe the successful pivot of TLTC from a fully in-person single-day multidisciplinary clinic with a multidisciplinary tumor board (MDTB) to a fully virtual experience, thereby maintaining access to this unique clinical model of patient care during the COVID-19 pandemic. The ability to pivot from in-person clinical visits to completely virtual visits increases patient access to care and enables more physicians to participate. Areas for future study include the impact on patient experience, clinical outcomes, and cost-effectiveness of this high-resource model.

Indexed as

Carcinoma, HepatocellularCOVID-19Liver NeoplasmsTelemedicineHumansPandemicsTexascoronavirus disease 2019 (COVID-19)hepatocellular carcinoma (HCC)multidisciplinary carepalliative careTelemedicine

Identifiers

PMID37953220
PMCPMC11198968
OpenAlexW4388616151

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.